Remember Me
Or use your Academic/Social account:


Or use your Academic/Social account:


You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.


Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message


Verify Password:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Kohberg, Charlotte; Andersen, Charlotte Uggerhøj; Bendstrup, Elisabeth (2016)
Publisher: Co-Action Publishing
Journal: European Clinical Respiratory Journal
Languages: English
Types: Article
Subjects: Review Article, interstitial lung disease, review, opioid, Interstitial Lung disease; ILD; Chronic obstructive lung disease; COPD; Morphine; opioid; dyspnea; review,, dyspnea, chronic obstructive lung disease, COPD, morphine

Classified by OpenAIRE into

mesheuropmc: respiratory tract diseases
Background: Idiopathic pulmonary fibrosis (IPF) is the most common among the idiopathic interstitial pneumonias and has the worst prognosis, with a median survival of 3–5 years. The most common symptom in IPF is dyspnea, impacting on the patient’s quality of life and life expectancy. Morphine in the treatment of dyspnea has been investigated but with conflicting results. This review aims to clarify the role of opioids in the treatment of dyspnea in patients with IPF.Methods: A literature search was performed using the MeSH and PubMed databases. As only very few studies included patients with IPF, studies conducted primarily with patients with chronic obstructive pulmonary disease were also included. In total, 14 articles were found.Results: Seven studies reported use of systemic morphine and seven studies of inhaled morphine. Five of the seven studies investigating systemic administration detected an improvement in either dyspnea or exercise capacity, whereas no beneficial effect on dyspnea was detected in any study using inhaled morphine. No severe adverse effects such as respiratory depression were reported in any study, although constipation was reported as a notable adverse effect.Conclusions: Results were inconsistent, but in some studies systemic morphine administration showed a significant improvement in the dyspnea score on a visual analog scale without observation of severe side effects. Nebulized morphine had no effect on dyspnea.Keywords: interstitial lung disease; chronic obstructive lung disease; COPD; morphine; opioid; dyspnea; reviewCitation: European Clinical Respiratory Journal 2016, 3: 30629 - http://dx.doi.org/10.3402/ecrj.v3.30629

Share - Bookmark

Cite this article